| Original language | English |
|---|---|
| Article number | 1846358 |
| Journal | OncoImmunology |
| Volume | 9 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 1 Jan 2020 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: OncoImmunology, Vol. 9, No. 1, 1846358, 01.01.2020.
Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Novel galenic formulations for delivering immunochemotherapies
T2 - kill intelligently, remove the checkpoint and let the T cells in!
AU - Kepp, Oliver
AU - Kroemer, Guido
N1 - Funding Information: OK receives funding from the DIM Elicit; GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; AMMICa US23/CNRS UMS3655; Association pour la recherche sur le cancer (ARC); Association “Ruban Rose”; Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China [GDW20171100085], Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology [ANR-18-IDEX-0001]; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).
PY - 2020/1/1
Y1 - 2020/1/1
UR - http://www.scopus.com/inward/record.url?scp=85096084819&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2020.1846358
DO - 10.1080/2162402X.2020.1846358
M3 - Editorial
C2 - 33244441
AN - SCOPUS:85096084819
SN - 2162-4011
VL - 9
JO - OncoImmunology
JF - OncoImmunology
IS - 1
M1 - 1846358
ER -